Delcath Systems IncNASDAQ:DCTH
- LAST PRICE9.1350
- TODAY'S CHANGE (%)0.2650 (2.9876%)
- Bid / Lots8.8700/ 1
- Ask / Lots9.2900/ 1
- Open / Previous Close9.0100 / 8.8700
- Day Range
- 52 Week Range
- Volume202,953
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DCTH |
|---|---|---|
| 09:32 ET | 2149 | 9.0375 |
| 09:36 ET | 7208 | 9 |
| 09:43 ET | 2864 | 9.015 |
| 09:50 ET | 350 | 9.0359 |
| 09:54 ET | 900 | 8.93 |
| 09:57 ET | 482 | 8.8832 |
| 09:59 ET | 700 | 9.01 |
| 10:01 ET | 100 | 9 |
| 10:03 ET | 700 | 8.985 |
| 10:06 ET | 12322 | 9 |
| 10:08 ET | 459 | 9 |
| 10:10 ET | 100 | 8.98 |
| 10:12 ET | 684 | 8.93 |
| 10:14 ET | 100 | 8.92 |
| 10:15 ET | 2096 | 8.97 |
| 10:17 ET | 1387 | 9.0133 |
| 10:19 ET | 400 | 8.97 |
| 10:26 ET | 140 | 8.97 |
| 10:28 ET | 200 | 8.98 |
| 10:32 ET | 499 | 8.975 |
| 10:33 ET | 100 | 9 |
| 10:35 ET | 1025 | 9.03 |
| 10:39 ET | 1806 | 9.0127 |
| 10:42 ET | 750 | 9.0368 |
| 10:44 ET | 864 | 9.035 |
| 10:46 ET | 306 | 9.06 |
| 10:51 ET | 300 | 9.035 |
| 10:55 ET | 100 | 9.06 |
| 11:00 ET | 4309 | 9.035 |
| 11:02 ET | 1500 | 9.0399 |
| 11:11 ET | 400 | 9.04 |
| 11:13 ET | 3860 | 9.05 |
| 11:18 ET | 100 | 8.99 |
| 11:31 ET | 125 | 8.975 |
| 11:33 ET | 2800 | 9 |
| 11:42 ET | 300 | 8.97 |
| 11:44 ET | 406 | 9 |
| 11:51 ET | 100 | 8.985 |
| 12:00 ET | 100 | 9.01 |
| 12:02 ET | 627 | 8.98 |
| 12:03 ET | 2862 | 8.96 |
| 12:05 ET | 160 | 8.99 |
| 12:07 ET | 3801 | 8.99 |
| 12:14 ET | 200 | 8.98 |
| 12:16 ET | 1500 | 8.97 |
| 12:18 ET | 100 | 8.975 |
| 12:21 ET | 1400 | 8.97 |
| 12:23 ET | 152 | 8.96 |
| 12:30 ET | 200 | 8.97 |
| 12:32 ET | 2246 | 8.96 |
| 12:38 ET | 1255 | 8.96 |
| 12:39 ET | 618 | 8.975 |
| 12:43 ET | 2574 | 8.9699 |
| 12:50 ET | 100 | 8.98 |
| 12:52 ET | 127 | 8.97 |
| 12:56 ET | 1400 | 8.99 |
| 12:57 ET | 395 | 9.02 |
| 01:03 ET | 2529 | 9.07 |
| 01:06 ET | 600 | 9.055 |
| 01:08 ET | 600 | 9.06 |
| 01:10 ET | 3825 | 9.02 |
| 01:14 ET | 200 | 9.015 |
| 01:15 ET | 100 | 9.02 |
| 01:24 ET | 600 | 9.03 |
| 01:26 ET | 869 | 9.04 |
| 01:35 ET | 100 | 9.03 |
| 01:39 ET | 100 | 9.03 |
| 01:48 ET | 100 | 9.02 |
| 01:51 ET | 100 | 9.04 |
| 01:53 ET | 591 | 9.07 |
| 01:55 ET | 661 | 9.08 |
| 02:00 ET | 640 | 9.09 |
| 02:02 ET | 3092 | 9.12 |
| 02:04 ET | 16957 | 9.18 |
| 02:08 ET | 676 | 9.15 |
| 02:11 ET | 400 | 9.15 |
| 02:13 ET | 1098 | 9.11 |
| 02:22 ET | 250 | 9.13 |
| 02:24 ET | 379 | 9.1 |
| 02:26 ET | 300 | 9.085 |
| 02:29 ET | 112 | 9.1 |
| 02:31 ET | 300 | 9.09 |
| 02:33 ET | 827 | 9.06 |
| 02:36 ET | 100 | 9.065 |
| 02:40 ET | 5600 | 9.0172 |
| 02:44 ET | 100 | 9.025 |
| 02:47 ET | 1000 | 9.04 |
| 02:51 ET | 211 | 9.03 |
| 02:56 ET | 720 | 9.06 |
| 02:58 ET | 502 | 9.07 |
| 03:00 ET | 900 | 9.08 |
| 03:02 ET | 5243 | 9.09 |
| 03:05 ET | 100 | 9.07 |
| 03:07 ET | 583 | 9.07 |
| 03:09 ET | 808 | 9.1 |
| 03:12 ET | 909 | 9.125 |
| 03:16 ET | 300 | 9.085 |
| 03:20 ET | 100 | 9.1 |
| 03:27 ET | 127 | 9.085 |
| 03:32 ET | 958 | 9.12 |
| 03:34 ET | 1529 | 9.11 |
| 03:36 ET | 600 | 9.08 |
| 03:38 ET | 1100 | 9.085 |
| 03:39 ET | 1500 | 9.08 |
| 03:41 ET | 1000 | 9.09 |
| 03:43 ET | 419 | 9.11 |
| 03:45 ET | 1463 | 9.11 |
| 03:48 ET | 400 | 9.129 |
| 03:50 ET | 200 | 9.11 |
| 03:52 ET | 207 | 9.1 |
| 03:54 ET | 4227 | 9.13 |
| 03:56 ET | 827 | 9.11 |
| 03:57 ET | 1215 | 9.135 |
| 03:59 ET | 13077 | 9.135 |
Sep 20, 2024
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:01PM ET on Friday Sep 20, 2024 by Dow Jones
4:01PM ET on Friday Sep 20, 2024 by Dow Jones
Sep 16, 2024
Aug 28, 2024
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients, from 4:01PM ET on Wednesday Aug 28, 2024 by Dow Jones
4:01PM ET on Wednesday Aug 28, 2024 by Dow JonesDelcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, from 4:01PM ET on Wednesday Aug 28, 2024 by Dow Jones
4:01PM ET on Wednesday Aug 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Delcath Systems Inc | 248.4M | -3.6x | --- |
Alpha Teknova Inc | 240.4M | -5.1x | --- |
Utah Medical Products Inc | 232.7M | 15.4x | +2.27% |
Senseonics Holdings Inc | 185.5M | -2.6x | --- |
CVRx Inc | 183.9M | -3.4x | --- |
Pulmonx Corp | 323.4M | -5.5x | --- |
Company Information
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Contact Information
- Headquarters
- 566 Queensbury AvenueQUEENSBURY, NY, United States 12804
- Phone
- 518-743-8892
- Fax
- 212-489-2102
Executives
- Independent Chairman of the Board
- John Sylvester
- Chief Executive Officer, Director
- Gerard Michel
- Chief Operating Officer
- Martha Rook
- Executive Vice President - Global Head of Operations
- John Purpura
- Senior Vice President - Finance, Chief Accounting Officer, Executive Officer
- Sandra Pennell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $248.4M |
|---|---|
Revenue (TTM) | $11.9M |
Shares Outstanding | 28.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-2.55 |
Book Value | $0.69 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | 20.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -303.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
